Close menu




May 20th, 2022 | 11:35 CEST

Capital increase? What you need to know! TUI, Triumph Gold, Steinhoff

  • Investments
Photo credits: pixabay.com

To be successful as a company, you need not only motivated employees, functioning machines and brilliant ideas, but also capital. Investments are the cornerstone for growth and success on the stock market. But why are companies that raise "fresh money" on the market regularly punished? Is it possibly related to communication and how the funds are used? We take a closer look at three stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: TUI AG NA O.N. | DE000TUAG000 , TRIUMPH GOLD CORP. | CA8968121043 , STEINHOFF INT.HLDG.EO-_50 | NL0011375019

Table of contents:


    TUI: Salami tactics displease the market

    TUI's share price has recently taken a significant hit. The reason is a capital increase with the purpose of repaying the state aid provided during the pandemic. Lufthansa took a similar step months ago. At the time, however, the market interpreted the measure as a signal of strength. Finally, being independent again and taking off. Things look different at TUI at the moment. Perhaps this is because the travel group is not entirely paying off its state aid. Also, the capital increase is already the third step of this kind since 2021. At this point, the transaction has a "whiff of scandal" to it.

    If a capital increase does not exceed the 10% mark of the share capital, the Company can waive subscription rights for existing shareholders. These subscription rights ensure that the ownership structure can remain the same after a capital increase or that existing shareholders can at least sell their subscription rights and, in this way, receive compensation for the dilution. TUI has a major Russian investor on board who is now on the EU sanctions list, so a large capital increase with subscription rights was not possible. On the one hand, the current salami tactics mean that a liberating blow for TUI is not forthcoming and that shareholders' stakes are being diluted - after all, new shares are coming onto the market. TUI is heading for below EUR 2.

    Triumph Gold: Step by step to success

    Capital increases are also an issue for investors in the commodity market. The earlier a company is in its development stage, the more likely it is to rely on such measures. Instead, major investors and strategic partners are rewarded with warrants that allow them to buy additional shares in return for a payment that is usually higher than the current share price. That injects capital into companies' coffers on the commodities market twice over, enabling them to continue on their growth path. However, if the market as a whole falters and prices appear to be cemented, there can also be pressure on the share after capital increases. That is what happened with Triumph Gold in recent months.

    The Company was able to provide itself with sufficient capital in 2020 at the peak of the gold bull market - the price of the new shares was CAD 0.20 at that time. A warrant was granted at CAD 0.30 on a three-year view. In the meantime, the share price is more than 50% lower. Many investors from the capital increase are likely to have parted with the value and only hold the warrants. From today's perspective, it seems unlikely that these will run into the money, but investors must consider how quickly things can sometimes move on the capital market. In 2020, the value went from CAD 0.11 to CAD 0.28 within four months. Since Triumph Gold has drilled successfully in recent years and even discovered an entirely new zone of mineralization recently, the stock should be on some investors' minds. If the market turns around like in 2020, the hard work of the past years could be a cornerstone for a positive development of the share. Currently, risk also seems to be priced in because of possible financing rounds. But opportunities can also arise from this. Triumph is a case for the watch list.

    Steinhoff: Saved, but at what price?

    The example of Steinhoff shows that it is sometimes more complicated to have funds than to need them. The ailing furniture group from South Africa argued with creditors for years. During this phase, there was some restructuring. The result: countless bonds under various conditions. Although the measures ensured the Company's survival years ago, the financial situation still weighs on the stock today. Coupled with legal disputes, this is not a convincing investment story.


    When companies need capital, the market takes notice. What weighs on the share price most is uncertainty or capital measures without meaningful investments. TUI's salami tactics, which have the sole purpose of paying off the state, are an example of this. Things are different for emerging mining companies like Triumph Gold. Here, investors know that capital is going into work on a promising property in Canada's Yukon. The Company's steady work over the past few years can pay dividends, especially during challenging market periods. Frugality is not infrequently rewarded.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read